Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Tirzepatide (brand Mounjaro), a dual GIP/GLP-1 agonist, was approved for diabetes (2022) and for weight loss as Zepbound (2023)
Ageing of the brain is paralleled by an increase of the glutamate to glutamine ratio indicating abnormal operation of the glutamate (GABA)-glutamine shuttle
Clinical studies on GLP-1 compounds show dose-dependent effects, meaning lower doses produce measurable appetite suppression and metabolic benefitstypically 8-12% weight loss over 6-12 months at microdose levels
(2021) showed that the GLP-1 RA drug class may be associated with a relative risk reduction for clinical kidney outcomes of 21% (HR 0.79
Some scientists are concerned about the rates of vision loss among patients who take Zepbound and other GLP-1s
